MRKMerck & Co., Inc.SEC EDGAR
Use with Claude or ChatGPT

Merck & Co., Inc. (MRK) Overview

Healthcare • NYSE • CIK 0000310158

Loading...

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Market Cap
$362.27B
P/E (TTM)
147.7x
Rev Growth (TTM)
+4.9%
Net Margin (TTM)
3.6%
FCF Yield (TTM)
4.1%
FCF Margin (TTM)
21.9%
Figures as of September 30, 2026
Data coverage notes

Operating income: no tagged operating-income figure (OperatingIncomeLoss) resolved for the trailing twelve months, so MetricDuck computes revenue minus total costs and expenses as it totals them; it is not a figure the filing tags as operating income. Operating margin, interest coverage, ROIC and EV/EBIT are built on it; no EBIT is synthesised.

Filings

Primary-source SEC disclosures, read end-to-end. SEC figures cite the filing they come from.

10-Q2026 Q32026-11-04source
8-KEarnings2026-10-29source
8-KOct 20262026-10-13source
10-Q2026 Q22026-08-07source
8-KEarnings2026-08-04source
What your agent reads

Investor Relations

www.merck.com/investor-relations

Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.

Company-published, not SEC-audited

Earnings

Q3
18 days ago
8-K release
Revenue
$18.09B
+4.7%
Net Income
$5.07B
-12.4%
EPS
$2.04
-12.1%
Earnings call2026 Q1· issuer-publishedtranscript
Most recent quarterly earnings snapshot

Cash Flow Health

Free Cash Flow8/8 positive
TTM$14.7B
Q3 '26
$5.5B+23%
Q2 '26
$4.5B+53%
FCF Margin
TTM21.9%
Q3 '2630.5%+13%
Sector: 3.0%Top 25%
OCF Margin
27.8%
OCF/NI7.62x
CapEx Coverage
4.7x
FCF Yield4.1%
FCF Growth (3Y)+4%
Cash Conversion Cycle
109 days
DSO: 66+DIO: 123−DPO: 80
Factsheet →
Cash flow trends & capital efficiency

Capital Allocation

Total Shareholder YieldTTM
TTM3.3%
Div Yield2.3%
+
Buyback (TTM)1.0%
Dividend & Payout Metrics
Dividend Yield (TTM)2.3%
FCF Payout Ratio57.2%
Free Cash Flow (TTM)$14.7B
Stock Repurchases (TTM)$3.5B
Capital Return / FCF81.4%
Shares Outstanding (YoY)-0.7%↓ Buyback
Est. Dividends Paid (TTM)$8.4B
Shows how management rewards shareholders

Valuation Metrics

Price-to-EarningsTTM
147.7x
Volatile
8Q: 11.1x-3490%
Valuation Lenses
Earnings
147.7x
vs – sector
Cash Flow
27.6x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
42.1P/E per %ROIC
ROIC: 3.5%
Shareholder Returns
Dividend
2.3%
Buyback
1.0%
Total Yield
3.3%
Market Cap$362.27B
EV$406.39B

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Multi-angle valuation analysis with sector context

Margins & Efficiency

ROIC 69th pctile
Profitability Cascade
Gross
71.8%
Operating
9.2%
Above Avg in sector
Net
3.6%
Margins Unknown
Return on Invested CapitalTTM
3.5%
Moderate
-0.2% YoY8Q: 20.2%-20.2%
P25MedianP75
69th pctl (med: -7.7%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
5.1%
8Q: 27.0%
Asset Turnover
0.51x
8Q: 0.53x
Leverage (1+D/E)
2.20x
D/E: 1.20x
DuPont: 5.7% ≈ 3.5% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
2.64x
8Q:2.59x
+10.5%
Invested Cap Turn
0.81x
8Q:0.85x
-3.3%
CapEx Intensity
4.7%
8Q:4.9%
CapEx/Depreciation
1.16x
FCF vs Net Margin Gap+18.2 pts
Margin trends, ROIC, and capital efficiency

Balance Sheet & Solvency

ND/EBITDA 4.2x
Net Debt / EBITDA
4.2xNet Debt: $44.13B
Interest Coverage
3.2x
Leverage Metrics
Debt-to-Equity
1.20x
Balance sheet risk & solvency analysis

Related Research

3 related posts